<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329693</url>
  </required_header>
  <id_info>
    <org_study_id>FE999051 CS01</org_study_id>
    <nct_id>NCT00329693</nct_id>
  </id_info>
  <brief_title>Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide &amp; Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women included in this study are undergoing controlled ovarian hyperstimulation for assisted
      reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No data to be entered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OHSS</measure>
    <time_frame>41 days after hCG injection</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily Tablets Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily Tablets Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily Tablets Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily Tablets Dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norprolac</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norprolac</intervention_name>
    <description>Quinagolide</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norprolac</intervention_name>
    <description>Quinagolide</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norprolac</intervention_name>
    <description>Quinagolide</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed Informed Consent Form, prior to screening evaluations

          2. In good physical and mental health

          3. Pre-menopausal females between the ages of 21-37 years (both inclusive) at the time of
             randomisation

          4. Infertility for at least 1 year before randomisation, except for proven bilateral
             tubal infertility

        Exclusion Criteria

          1. Any clinically significant systemic disease

          2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

          3. History of recurrent miscarriage

          4. Undiagnosed vaginal bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Barcelona, Ronda General Mitre, 14</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Bilbao, Paseo Landabarri, 1</name>
      <address>
        <city>Leioa-Bizkaia</city>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Madrid, Santiago de Compostela, 88</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Murcia, Navegante Macías del Poyo, 5, Edificio Delfín-Barrio La Flota</name>
      <address>
        <city>Murcia</city>
        <zip>30007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla, Avda. República Argentina, 58</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Valencia, Plaza de la Policía Local, 3</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Vigo, Plaza Francisco Fernández del Riego, 7 (Plaza Elíptica)</name>
      <address>
        <city>Vigo (Pontevedra)</city>
        <zip>36203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quinagolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

